Clinical trials: Nephrocalcinosis
Nephrolithiasis, Nephrocalcinosis
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults.
- Conditions
- Nephrolithiasis, Nephrocalcinosis, Hypercalciuria
- Trial name
- FLUCOLITH (NCT04495608)
- Testing
- Fluconazole
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Autosomal Dominant Hypocalcemia
ADH1 and ADH2 Disease Monitoring Study (DMS)
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease…
- Trial name
- CLARIFY (NCT05227287)
- Where
- 27 sites in United States, Australia and 11 more
- Volunteers
- 95 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Nephrocalcinosis
Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric Onset
The aim of the study is to build a database of pediatric patients affected by nephrolithiasis or nephrocalcinosis in order to investigate their clinical and epidemiological characteristics.
- Trial name
- Calcolosi-kid (NCT07874087)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Paraffinoma, Granuloma, Foreign-Body
The GranStone Trial
This study will investigate whether treatment with empagliflozin or losartan can reduce the risk of kidney stone formation in patients with paraffin disease, a condition caused by the injection of paraffin oil into muscle tissue…
- Trial name
- NCT07828002
- Testing
- empagliflozin (Jardiance) 25 mg, Losartan 100 mg
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Martin Blomberg Jensen